BIOQ Stock Overview
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
My Notes
NewNotes are coming soon
Bioqual, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$81.80 |
| 52 Week High | US$96.00 |
| 52 Week Low | US$57.00 |
| Beta | -0.17 |
| 1 Month Change | 0% |
| 3 Month Change | 12.05% |
| 1 Year Change | -9.11% |
| 3 Year Change | 75.91% |
| 5 Year Change | 121.98% |
| Change since IPO | 27,165.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| BIOQ | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 1.7% | 1.7% |
| 1Y | -9.1% | -11.2% | -9.6% |
Return vs Industry: BIOQ exceeded the US Life Sciences industry which returned -11.2% over the past year.
Return vs Market: BIOQ matched the US Market which returned -9.6% over the past year.
Price Volatility
| BIOQ volatility | |
|---|---|
| BIOQ Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 11.7% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: Insufficient data to determine BIOQ's volatility over the past 3 months.
Volatility Over Time: Insufficient data to determine BIOQ's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | n/a | Mark Lewis | https://www.bioqual.com |
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays.
Bioqual, Inc. Fundamentals Summary
| BIOQ fundamental statistics | |
|---|---|
| Market Cap | US$73.16m |
| Earnings (TTM) | US$5.42m |
| Revenue (TTM) | US$67.96m |
13.5x
P/E Ratio1.1x
P/S RatioIs BIOQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIOQ income statement (TTM) | |
|---|---|
| Revenue | US$67.96m |
| Cost of Revenue | US$50.79m |
| Gross Profit | US$17.18m |
| Other Expenses | US$11.76m |
| Earnings | US$5.42m |
Last Reported Earnings
Nov 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.06 |
| Gross Margin | 25.27% |
| Net Profit Margin | 7.98% |
| Debt/Equity Ratio | 54.4% |
How did BIOQ perform over the long term?
See historical performance and comparison